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AMPK-independent inhibition 
of human macrophage ER stress 
response by AICAR
Marcel Boß1, Yvette Newbatt2, Sahil Gupta1, Ian Collins2, Bernhard Brüne1,3 & 
Dmitry Namgaladze1
Obesity-associated insulin resistance is driven by inflammatory processes in response to metabolic 
overload. Obesity-associated inflammation can be recapitulated in cell culture by exposing 
macrophages to saturated fatty acids (SFA), and endoplasmic reticulum (ER) stress responses 
essentially contribute to pro-inflammatory signalling. AMP-activated protein kinase (AMPK) is a central 
metabolic regulator with established anti-inflammatory actions. Whether pharmacological AMPK 
activation suppresses SFA-induced inflammation in a human system is unclear. In a setting of hypoxia-
potentiated inflammation induced by SFA palmitate, we found that the AMP-mimetic AMPK activator 
5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) potently suppressed upregulation of 
ER stress marker mRNAs and pro-inflammatory cytokines. Furthermore, AICAR inhibited macrophage 
ER stress responses triggered by ER-stressors thapsigargin or tunicamycin. Surprisingly, AICAR acted 
independent of AMPK or AICAR conversion to 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl 
monophosphate (ZMP) while requiring intracellular uptake via the equilibrative nucleoside transporter 
(ENT) ENT1 or the concentrative nucleoside transporter (CNT) CNT3. AICAR did not affect the initiation 
of the ER stress response, but inhibited the expression of major ER stress transcriptional effectors. 
Furthermore, AICAR inhibited autophosphorylation of the ER stress sensor inositol-requiring enzyme 
1α (IRE1α), while activating its endoribonuclease activity in vitro. Our results suggest that AMPK-
independent inhibition of ER stress responses contributes to anti-inflammatory and anti-diabetic 
effects of AICAR.
The importance of metabolism in regulating immunity and inflammation is now widely recognized1,2. 
AMP-activated protein kinase (AMPK) is the central hub of metabolic regulation, rewiring cellular metabolic 
fluxes in response to energy loss to decrease anabolic and increase catabolic processes3. In innate immune 
cells, AMPK suppresses inflammatory signalling4 and promotes anti-inflammatory macrophage polarization5. 
The anti-inflammatory potential of AMPK is particularly interesting because of its potential application for 
anti-diabetic therapies. Current concepts on the development of insulin resistance and type 2 diabetes consider 
chronic inflammatory response caused by obesity-driven adipose tissue expansion to be a major contributing 
factor to disease progression. Macrophages recruited to the expanding adipose tissue undergo pro-inflammatory 
polarization6,7, which can be mimicked in vitro by macrophages exposure to saturated fatty acids (SFA), such as 
palmitate7–9. Mechanistically, SFA-induced inflammation was explained by activation of toll-like receptors10,11 
as well as induction of intracellular stress signalling cascades, in particular, c-Jun N-terminal kinase (JNK)12 
and endoplasmic reticulum (ER) stress response13. ER stress responses, mediated by the activation of three 
major upstream effectors, i.e. protein kinase R-like endoplasmic reticulum kinase (PERK), endoribonuclease 
inositol-requiring enzyme 1 (IRE1), and the activating transcription factor 6 (ATF6), can be triggered by SFAs 
through increasing the degree of saturation of ER membrane phospholipids14, provoking direct activation of 
PERK and IRE1. IRE1, in turn, activates JNK via IRE1 association with the adaptor protein tumour necrosis 
factor receptor associated factor 2 (TRAF2)15. SFA-induced ER stress, together with other mechanisms, such as 
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increased Src kinase association with lipid rafts16, connect fatty acid metabolism to inflammatory signalling. On 
the other hand, increasing fatty acid mitochondrial oxidation, by diverting the fatty acid flux towards catabolism, 
attenuates ER stress and inflammation in palmitate-treated macrophages17. AMPK is a well-known activator of 
fatty acid oxidation (FAO) and indeed its absence in macrophages increased palmitate-induced inflammatory 
responses, partly through diminished FAO18. An alternative mechanism how AMPK attenuates inflammation in 
palmitate-treated macrophages suggestively involves activation of the protein deacetylase (Sirt1)19.
Considering the therapeutic potential of AMPK during metabolic and inflammatory disorders, it is criti-
cal to understand mechanistic aspects and possible off-target effects of clinically employed AMPK activa-
tors. AMPK activators can be divided in three classes: i) molecules converted to AMP mimetics, such as 
5-aminoimidazole-4-carboxamide-1-β -D-ribofuranoside (AICAR), ii) allosteric activators such as A769662 or 
iii) drugs inhibiting mitochondrial ATP production and elevating AMP, such as the widely used anti-diabetic drug 
metformin20. Most of AMPK activators also show biological effects unrelated to AMPK activation. Importantly, 
AMPK-independent inhibition of inflammation was reported for metformin21 and for AICAR22,23. However, the 
exact mechanism of how AICAR inhibits inflammation is still unresolved.
Here we report that AICAR profoundly inhibits SFA-induced ER stress and inflammatory responses to palmi-
tate in human macrophages. Furthermore, AICAR turned out as a general inhibitor of the ER stress response, which 
occurs independently of the conversion of AICAR to 5-aminoimidazole-4-carboxamide-1-β -D-ribofuranosyl 
monophosphate (ZMP) and hence, AMPK activation. Mechanistically, AICAR inhibited mRNA and protein 
induction of the major transcriptional effectors of the ER stress response, without interfering with initiation of 
ER stress.
Results
AICAR inhibits hypoxia-enhanced palmitate-induced inflammation in human macrophages. 
AMPK activation is considered to be anti-inflammatory1, but the ability of pharmacologic AMPK activators 
to block inflammatory responses is still unclear. We used an experimental system of hypoxia-enhanced palmi-
tate-induced inflammation in primary human macrophages8 to test distinct classes of AMPK activators for their 
effect on palmitate-induced ER stress and inflammatory markers. This experimental system reflects a pro-in-
flammatory, hypoxic milieu of hypertrophic adipose tissue in obesity. Analysing phosphorylation of AMPK at 
T172 as a marker of AMPK activation, we noticed that palmitate moderately activated AMPK, while hypoxia 
reduced this activity (Fig. 1A), suggesting that AMPK is not activated under palmitate/hypoxic exposure. As 
observed previously8, c-Jun phosphorylation, a readout of an inflammatory response, increased under hypoxia/
palmitate (Fig. 1A). We then chose drugs activating AMPK allosterically (A769662, salicylate), changing the 
adenylate energy charge (phenformin, R419), or mimicking AMP (AICAR)24,25 at concentrations causing sim-
ilar AMPK activation as followed by phosphorylation of the AMPK substrate acetyl-CoA carboxylase (ACC) 
(Fig. 1B). In parallel, we analysed the markers of ER stress, i.e. phospho-IRE1, and inflammation (phospho-cJun). 
Of all AMPK activators only AICAR consistently inhibited palmitate-induced IRE1 and cJun phosphorylation 
(Fig. 1B). mRNA expression of ER stress-responsive genes Grp78 and CHOP as well as inflammatory cytokines 
IL-1β, TNFα, and IL-6 confirmed that AICAR was the most potent inhibitor (Fig. 1C). Among other AMPK 
activators only phenformin inhibited ER stress responses and cytokines, whereas R419 and salicylate reduced 
only IL1β and IL6 mRNA expression. A769662 was without any effect at all. None of the AMPK activators inhib-
ited the expression of hypoxia-sensitive GLUT1 mRNA, suggesting that signalling through hypoxia-inducible 
factor (HIF) remains intact. Analysis of IL1β , TNFα and IL-6 protein secretion after hypoxia/palmitate treat-
ment revealed divergent effects of AMPK activators on different cytokines (Fig. 1D). Remarkably, only AICAR 
consistently inhibited the secretion of all three cytokines. Our data indicate that AMPK activators suppress SFA-
triggered inflammatory responses to a variable degree, suggesting that AICAR may block palmitate-induced ER 
stress and inflammation through mechanisms unrelated to AMPK activation.
We went on to investigate mechanisms how AICAR inhibits SFA-induced inflammatory responses. Although 
previous studies suggested the involvement of Sirt1 and FAO in attenuating SFA-induced inflammation by 
AMPK18,19, the AICAR effect in our study was neither reversed by the Sirt1 inhibitor Ex527, nor by the FAO 
blocker etomoxir (Supplementary Figure S1A). Active AMPK also interferes with mechanistic target of rapa-
mycin complex 1 (mTORC1), which may attenuate inflammatory cell responses1. However, treatment of mac-
rophages with the mTORC1 inhibitor rapamycin did not influence the expression of inflammatory and ER stress 
markers after hypoxia/palmitate (Supplementary Figure S1A). Furthermore, AICAR did not affect triglyceride 
levels in palmitate-treated hypoxic macrophages (Supplementary Figure S1B), suggesting that changes in fatty 
acid metabolism are unlikely to explain AICAR effects.
AICAR inhibits ER stress responses in macrophages in AMPK-independent manner. With 
no indication towards the previously described anti-inflammatory mechanisms of AMPK in our system, we 
followed the observation that only AICAR suppressed both, IRE1 phosphorylation and ER stress markers in 
palmitate-treated macrophages. Thus, we questioned whether AICAR acts as a general inhibitor of ER stress 
responses in macrophages. Therefore, we used the prototype ER stress inducers thapsigargin and tunicamycin in 
cells pre-treated with AICAR. AICAR largely attenuated induction of ER stress mRNA markers by thapsigargin 
and tunicamycin (Fig. 2A).
ER stress responses are executed by three major branches initiated by the ER stress sensors PERK, IRE1, 
and ATF6. To evaluate whether AICAR inhibits all three branches we examined PERK activation by following 
phosphorylation of the eukaryotic initiation factor 2α (eIF2α ), a known PERK substrate. IRE1 activation was 
assessed by analysing pIRE1 and protein amounts of spliced X-box binding protein 1 (XBP1) as a readout of IRE1 
activity. In addition, we assessed the ATF6 branch by following accumulation of cleaved ATF6 in nuclear lysates. 
AICAR blocked thapsigargin and tunicamycin-induced IRE1 phosphorylation, accumulation of spliced XBP1 
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Figure 1. AICAR inhibits hypoxia/palmitate-induced ER stress and inflammation in hypoxic macrophages. 
(A,B) Western analysis of macrophages exposed to palmitate (PA) in the presence or absence of hypoxia and 
AMPK activators for 24 h. (C) mRNA expression of indicated genes in hypoxic macrophages treated for 24 h 
with palmitate and AMPK activators. (D) Cytokine secretion in hypoxic macrophages treated for 24 h with 
palmitate and AMPK activators. *p < 0.05. Data represent mean values ± SE of at least three independent 
experiments. Western Blot images are cropped scans either of the same or of the duplicate membranes probed 
with different antibodies.
www.nature.com/scientificreports/
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(Fig. 2B), but did not affect eIF2α phosphorylation. However, AICAR prevented the nuclear accumulation of 
activating transcription factor 4 (ATF4), a target and a major mediator of the PERK ER stress response pathway 
Figure 2. AICAR inhibits ER stress responses. (A) mRNA expression of ER stress markers, (B,C) Western 
analysis of cell lysates (B) or nuclear extracts (C).(D) mRNA expression of ATF4 and ATF6α in macrophages 
pre-exposed for 1 h to AICAR and treated with thapsigargin or tunicamycin for 6 h. (E) Western analysis of 
macrophages pre-exposed for 1 h to 0.5 mM AICAR in the absence or presence of ABT-702 and treated with 
thapsigargin for 6 h. (F) mRNA expression of CHOP and Grp78 in macrophages pre-exposed for 1 h to indicated 
concentrations of AICAR in the absence or presence of ABT-702 and treated with thapsigargin or tunicamycin for 
6 h. (G) Protein expression of AMPK 72 h post-transfection with control siRNA or AMPKα 1 siRNA. (H) mRNA 
expression of CHOP, Grp78 and AMPKα 1 in macrophages transfected with control siRNA or AMPKα 1 siRNA 
for 72 h prior to treatments with thapsigargin for 6 h with or without 1 h AICAR pre-exposure. *p < 0.05. Data 
represent mean values ± SE of at least three independent experiments. ns, non-specific band. Western Blot images 
are cropped scans either of the same or of the duplicate membranes probed with different antibodies.
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(Fig. 2C). We also noticed that AICAR blocked ATF4 mRNA induction by ER stressors (Fig. 2D), providing a 
possible explanation for the lack of ATF4 protein accumulation. Furthermore, nuclear levels of cleaved ATF6α 
protein as well as ATF6α mRNA expression after ER stress were also diminished in AICAR-treated macrophages 
(Fig. 2C,D). Thus, all three branches of the ER stress response are inhibited by AICAR.
To further investigate mechanisms how AICAR inhibits the ER stress response we first questioned whether 
AICAR demands AMPK activity or relies on AICAR conversion to ZMP, a step critical for AICAR to become 
an AMPK activator. AICAR phosphorylation to ZMP is catalysed by adenosine kinase. Addition of a potent 
adenosine kinase inhibitor ABT-702 prevented AICAR-induced AMPK activation as seen by the lack of ACC 
phosphorylation in AICAR-treated cells (Fig. 2E). Furthermore, AICAR-triggered inhibition of mTOR, analysed 
by following the phosphorylation of ribosomal S6 protein, was abolished by ABT-702 (Fig. 2E). However, ABT-
702 did not prevent the impact of AICAR on IRE1 phosphorylation or XBP1 splicing (Fig. 2E). In the presence 
of ABT-702, the inhibitory effect of AICAR on IRE1 phosphorylation and XBP1 splicing even appeared to be 
enhanced. Indeed, ABT-702 potentiated the ability of low AICAR concentrations to inhibit mRNA expression 
of ER stress markers (Fig. 2F). Collectively, these data suggested that AICAR acts upstream of its conversion 
to ZMP and independently of AMPK. Supporting these data, a knockdown of AMPK α 1 catalytic subunit 
(Fig. 2G) did not prevent inhibition of CHOP and Grp78 gene expression by AICAR (Fig. 2H). Dissociation 
of AICAR inhibition of ER stress and inflammatory response from AMPK activation was also observed in 
concentration-dependence experiments in palmitate-treated hypoxic macrophages (Supplementary Figure S2).
Nucleoside transporters involved into AICAR trafficking into macrophages. Although we 
observed pronounced effects of AICAR on ER stress responses in macrophages, these effects could not be repro-
duced in different cell lines, such as THP-1 monocytic cells or HEK293T cells (data not shown). We reasoned 
that differences in intracellular AICAR accumulation may explain cell type-specific effects of AICAR. Previous 
studies suggested that most of the AICAR trafficking into cells is mediated by dipyridamole-sensitive adenosine 
transporters of equilibrative nucleoside transporter (ENT) family (SLC29A1-4), but also concentrative nucleoside 
transporter (CNT) CNT3 (SLC28A3) can transport AICAR into cells26,27. Assessing mRNA levels of individual 
SLC28 and SLC29 family members in human primary macrophages revealed abundant expression of SLC29A3 
and SCL28A3 mRNAs (Fig. 3A; note the logarithmic scale of the graph), moderate amounts of SLC29A1 mRNA, 
whereas SLC29A2, SLC28A1, and SLC28A2 were marginally expressed. To question the roles of individual nucle-
oside transporters in AICAR - ER stress responses we inhibited SLC29A1/A2 with dipyridamole alone or in com-
bination with silencing SLC28A3 using RNA interference. This was followed by the analysis of mRNA expression 
of ER stress markers CHOP and Grp78 in response to thapsigargin. Silencing efficiency was verified by western 
analysis of SLC28A3 protein (Fig. 3B). Combining dipyridamole treatment with SLC28A3 silencing abolished 
the ability of AICAR to inhibit ER stress responses, whereas single treatments were only partly effective (Fig. 3C). 
Furthermore, overexpression of SLC28A3 in HEK293T cells allowed inhibition of ER stress responses to thapsi-
gargin or tunicamycin. This became evidenced by an attenuated CHOP and Grp78 expression, whereas AICAR 
showed limited efficacy in the absence of overexpressed SLC28A3 (Fig. 3D). In contrast, silencing of SLC29A3 
did not influence the inhibition of ER stress marker mRNA expression by AICAR (data not shown). These data 
suggest that entry of AICAR into cells through SLC29A1 and SLC28A3 transporters is necessary to interfere with 
ER stress in macrophages.
Effects of AICAR on IRE1α activity in vitro. With the information that AICAR prevented accumulation 
of phosphorylated IRE1 and spliced XBP1 proteins in ER-stressed macrophages we investigated the effects of 
AICAR on the IRE1-XBP1 branch of the UPR in more detail. Contrary to our expectations, analysis of XBP1 
splicing using primers specific to spliced and unspliced XBP1 mRNA revealed that the ER stress-induced splicing 
activity of IRE1 was not affected by AICAR (Fig. 4A,B). However, we observed lower mRNA levels of spliced 
XBP1, suggesting that XBP1 mRNA expression was attenuated by AICAR. IRE1 endoribonuclease activity also 
participates in a process of regulated IRE1-dependent decay (RIDD) of select mRNAs. To evaluate the influence 
of AICAR on RIDD, we analysed the mRNA expression of a well-characterized RIDD target mRNA BLOC1S1. 
Indeed, ER stress reduced BLOC1S1 mRNA expression in macrophages, which was unaffected by AICAR 
(Fig. 4C). Finally, we analysed the interaction of AICAR with recombinant IRE1α in vitro. AICAR bound to the 
ATP-binding site of IRE1α as evidenced by the Lanthascreen assay (Fig. 4D), and inhibited the IRE1α autophos-
phorylation in a DELFIA assay (Fig. 4E). However, when assessing endoribonuclease activity of IRE1α , AICAR 
appeared to activate IRE1α (Fig. 4F), which is consistent with the properties of reported type I kinase inhibitors 
of IRE1α 28,29. Thus, AICAR binds IRE1α and inhibits IRE1α kinase, but not its endoribonuclease activity in vitro. 
This is in agreement with the observations in cells.
Collectively, our observations indicate that AICAR, while not affecting initiation steps of the UPR, prevents 
accumulation of transcriptional effectors of the UPR, i.e., ATF4, sXBP1, and ATF6α both at mRNA and protein 
level. Remarkably, this effect is independent of AICAR to be converted to ZMP and to activate AMPK.
Discussion
The novel information of this study is the ability of AICAR to inhibit ER stress responses in an AMPK- 
independent manner. This may add to the potency of AICAR to prevent SFA-induced inflammation as com-
pared to other AMPK activators, since ER stress is a key factor in metabolic overload-triggered inflammatory 
responses. Remarkably, other AMPK activators are either less potent or completely unable (A769662) to inhibit 
palmitate-induced inflammation. Although cumulative evidence from mouse genetic models of AMPK deficiency 
strongly supports anti-inflammatory roles of AMPK, it is still unclear, whether AMPK is similarly active in the 
human vs. mouse innate immune system. Furthermore, the phenotype of genetic AMPK deficiency is definitely 
influenced by compensatory responses to AMPK loss, whereas pharmacological AMPK activators are supplied 
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to unperturbed cellular systems, making a comparison of the responses in these two settings difficult. Regardless 
of their impact on AMPK, several AMPK activators are known for AMPK-independent anti-inflammatory 
Figure 3. SLC29A1 and SLC28A3 facilitate the uptake of AICAR into macrophages. (A) mRNA 
expression of SLC28 and SLC29 family members in macrophages. (B) Protein expression of SLC28A3 72 h 
post-transfection with control siRNA or SLC28A3 siRNA. (C) mRNA expression of CHOP and Grp78 in 
macrophages transfected with control siRNA or SLC28A3 siRNA for 72 h prior to treatments with thapsigargin 
for 6 h with or without 1-h AICAR pre-exposure in the absence or presence of dipyridamole. (D) mRNA 
expression of CHOP and Grp78 in HEK293T cells transfected with GFP or SLC28A3 expressing plasmids and 
treated with thapsigargin or tunicamycin for 6 h with or without 1 h pre-exposure to indicated concentrations 
of AICAR. *p < 0.05. Data represent mean values ± SE of at least three independent experiments. Western Blot 
images are cropped scans of the same membrane probed with different antibodies.
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activities. This comprises mitochondrial complex I inhibition by biguanidines21, or targeting the NFκ B activation 
pathway by salicylate30. Although AICAR was known to inhibit inflammation in an AMPK-independent man-
ner22,23, molecular mechanisms remained unclear. The novelty of our data implies that under conditions of met-
abolic overload, inhibition of ER stress responses may contribute to the spectrum of anti-inflammatory AICAR 
effects. It is likely that the ability of AICAR to interfere with other aspects of pro-inflammatory macrophage 
signalling, as reported by others19,22,23, generates multi-pronged effects, resulting in the profound inhibition of 
inflammatory cytokine expression as observed in Fig. 1C.
Interestingly, AICAR does not attenuate initiation of ER stress responses, but inhibits mRNA and protein 
expression of all major transcriptional ER stress effectors, i.e. ATF4, spliced XBP1, and ATF6. Although initial 
results indicated a more selective response to the IRE1 branch of the ER stress, detailed examination of the IRE1 
cellular and in vitro activities revealed that AICAR may act as a type I kinase inhibitor of IRE128, inhibiting IRE1 
autophosphorylation and at the same time activating its RNase activity. The downstream signalling of IRE1 is still 
blocked by AICAR, since it apparently inhibits expression of total mRNA, and as a consequence, spliced XBP1. 
Although splicing activity of IRE1 is not inhibited by AICAR, its effect on IRE1 kinase activity may affect IRE1 
interaction with JNK15 and thus, contributes to attenuated JNK activity and subsequent inflammatory responses 
in AICAR-treated cells.
How AICAR inhibits ER stress-induced expression of ATF4, XBP1, and ATF6 remains unclear. To explore 
detailed mechanisms is complicated by fact that ER stress transcriptional effectors induce each other31,32. 
Furthermore, it is likely that AICAR also attenuates translation of ER stress effectors, as we observed that 
AICAR-treated macrophages contained reduced amounts of polysome-associated RNA (data not shown). 
Although AICAR may affect translation through AMPK-mediated inhibition of the mTORC1 pathway and phos-
phorylation of elongation factor 233, persistence of AICAR inhibitory effects in the absence of its conversion to 
ZMP, despite blocking mTORC1 activity and elongation factor 2 phosphorylation (Fig. 2E and data not shown), 
suggests that other mechanisms of translational attenuation may operate. This is similar to our observations on 
AICAR-mediated inhibition of the peroxisome proliferator activated receptor γ translation in the absence of its 
conversion to ZMP34. Interestingly, mTORC1 inhibition induced either by rapamycin or AMPK activators is infe-
rior to AICAR in alleviating palmitate-induced ER stress responses, arguing that the potency of AICAR is likely 
to represent a combination of transcriptional and translational effects.
Figure 4. AICAR inhibits IRE1α kinase, but not its splicing activity. (A) Q-PCR analysis of XBP1 splicing in 
macrophages pre-exposed for 1 h to AICAR and treated with thapsigargin or tunicamycin for 6 h. (B) RT-PCR 
analysis of XBP1 splicing in cells treated with AICAR and tunicamycin. The spliced (sXBP1) and unspliced 
(uXBP1) forms of XBP1 are indicated. (C) mRNA expression of BLOC1S1 in macrophages pre-exposed for 1 h 
to AICAR and treated with thapsigargin or tunicamycin for 6 h. (D) Analysis of AICAR binding to recombinant 
IRE1α . (E,F) Analysis of recombinant IRE1α kinase (E) and endoribonuclease (F) activity in the presence of 
indicated AICAR concentrations. *p < 0.05. Data represent mean values ± SE of at least three independent 
experiments.
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Our data also suggest that cellular levels of the CNT and ENT transporters as well as adenosine kinase activity 
critically determine the outcome of the AICAR effect. Corroborating previous findings that modulating CNT and 
ENT expression influences intracellular ZMP accumulation and hence the magnitude of ZMP-mediated intracel-
lular responses26, our study is the first to show that the endogenous CNT3 expression controls AICAR actions in 
macrophages. Of note, ENTs and CNTs are important drug targets to modulate the responses to nucleoside-based 
chemotherapies35. Similarly, we suggest that strategies aimed at enhancing ENT1 and CNT3 expression may 
promote AICAR anti-inflammatory and anti-ER-stress effects. Second, adenosine kinase activity may also deter-
mine the outcome of AICAR effects, switching it from ZMP-dependent (predominantly AMPK-mediated) to 
ZMP-independent pathways. Remarkably, in some cell contexts, such as acute myeloid leukemia, AMPK acti-
vation actually promotes ER stress36. Thus, it is interesting to test how adenosine kinase inhibitors will interact 
with AICAR systemically in the context of inflammatory diseases. We suggest that this combination can be more 
effective to suppress ER stress and inflammation and ameliorate metabolic disease. Considering that combina-
tions with adenosine kinase inhibitor may allow to lower the range of AICAR concentrations inhibiting ER stress 
towards levels observed in plasma of AICAR-treated volunteers37, our mechanistic finding may be thus translat-
able into human clinical setting.
Methods
Cell isolation and culture. Human peripheral blood mononuclear cells were isolated from buffy coats of 
anonymous donors (DRK-Blutspendedienst Baden-Württemberg-Hessen, Institut für Transfusionsmedizin und 
Immunhämatologie, Frankfurt, Germany) using Ficoll density centrifugation. Following 1 h culture in serum-
free RPMI medium, non-adherent cells were removed by vigorous washing. Remaining adhered monocytes 
were differentiated into macrophages by 7 d culture in RPMI 1640 medium containing 3% AB-positive human 
serum. Cells were treated (where indicated) with the following reagents: 500 μ M AICAR, 50 μ M etomoxir (both 
EMD Biosciences), 250 μ M A769662, 0.5 μ M ABT-702 (both Tocris), 1 μ M R419 (Rigel Phramaceuticals), 100 nM 
thapsigargin (Enzo Life Sciences), 10 μ M Ex527 (Selleckchem), 1 μ g/ml tunicamycin, 3 mM sodium salicylate, 
100 μ M phenformin, 100 nM rapamycin or 20 μ M dipyridamole (all Sigma-Aldrich). Palmitate (P-5585, Sigma-
Aldrich) was prepared by diluting a 100 mmol/L stock solution in 70% ethanol/0.1 mol/L NaOH into 10% fatty 
acid-free low endotoxin BSA (A-8806, Sigma-Aldrich, adjusted to pH 7.4) to obtain a palmitate:BSA molar ratio 
of 6:1 and a final palmitate concentration 500 μ M. Hypoxic incubations were performed using a hypoxic work-
station with 1% O2, 94% N2, 5% CO2 at 37⁰C (Invivo2 400, Ruskinn Technology). HEK293T cells were cultured in 
DMEM medium with 10% fetal calf serum, 100 U/ml penicillin, 100 μ g/ml streptomycin.
Studies conform to the principles outlined in the Declaration of Helsinki and were approved by the ethics 
committee of the Faculty of Medicine at Goethe-University Frankfurt. The ethics committee waived the necessity 
of written informed consent when using the buffy coats from anonymized blood donors.
siRNA transfection of macrophages. Silencing of AMPKα 1 and SLC28A3 in human primary mac-
rophages was achieved using corresponding siGENOME SMARTpools (Thermo Fisher Scientific) at 50 nM and 
Hiperfect transfection reagent (Qiagen). Cells were treated 72 h post-transfection.
Quantitative PCR. Total RNA of primary human macrophages was isolated using PeqGold RNAPure kit 
(PeqLab) and transcribed using cDNA Synthesis kit (Fermentas). Quantitative PCR was performed with iQ SYBR 
green Supermix (Bio-Rad) using the CFX96 system from Bio-Rad. Primer sequences for quantitative PCR can be 
obtained upon request. Expression was normalized to β -microglobulin.
XBP1 splicing analysis. To analyse XBP1 splicing 1 μ g of RNA was reverse-transcribed. The cDNA was PCR 
amplified using primers designed to encompass the splicing site38 with DNA Taq polymerase (26 cycles at 94 °C 
30 s, 60 °C 30 s, 72 °C 30 s). PCR products were resolved on 2% agarose gel, stained with ethidium bromide, and 
visualized using GenoSmart2 gel documentation system (VWR International).
Western blot. Protein lysates were separated on polyacrylamide gels followed by transfer onto nitrocellulose 
membranes. Membranes were incubated with antibodies against phospho-ACC (Ser79) (#3661), phospho-AMPK 
(Thr172) (#2531), phospho-eIF2α (Ser51) (#3398), phospho-cJun (Ser73) (#3270), phospho-S6 ribosomal pro-
tein (Ser240/244) (#2215), ACC (#3662), AMPK (#2532) (Cell Signalling Technology), sXBP1 (6196, BioLegend), 
phospho-IRE1 (Ser724) (ab124945, Abcam), ATF6 (NBP1-75478, Novus Biologicals), ATF4 (sc-200), or nucle-
olin (sc-13057) (Santa Cruz Biotechnology) followed by IRDye 800-coupled secondary antibodies (LICOR 
Biosciences). Blots were visualized and quantified using the Odyssey imaging system (LICOR Biosciences).
IL-1β detection in supernatants. Macrophage supernatants were analysed for IL-1β using a Cytometric 
Bead Array (CBA) (BD Biosciences) according to the manufacturer’s recommendations. Samples were measured 
using a LSRII/Fortessa flow cytometer (BD Biosciences) and analysed by FCAP Array software V1.0 (Soft Flow).
HEK293T cell transfection. 100000 cells plated in 6-well plates were cultured overnight and transfected 
with 1 μ g plasmid coding for GFP (pmaxGFP, Lonza) or SLC28A3 (RC210847, Origene) using JetPRIME trans-
fection reagent (Polyplus-transfection) according to manufacturer’s instructions.
Triglyceride determination. Cell pellets were lysed in PBS containing 1% Triton X-100. Determination of 
triglycerides in lysates was carried out using a commercial kit from Roche Diagnostics according to manufacturer 
instructions.
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Lanthascreen analysis of AICAR binding to IRE1α. AICAR binding to recombinant baculovirus- 
expressed His-tagged dephosphorylated IRE1α purified from Sf9 cells39 was assessed using Lanthascreen 
time-resolved fluorescence energy transfer assay (Thermo Scientific). A master mix (7.5 μ L) consisting of 
dephosphorylated IRE1α (50 nM), 2 nM biotinylated anti-His-tag antibody (PV6089, Thermo Scientific), 2 nM 
streptavidin-europium (PV5899, Thermo Scientific) diluted in assay buffer PV3189 (Thermo Scientific), 1 mM 
DTT (D0632, Sigma-Aldrich) was incubated with 7.5 μ L of 75 nM tracer (tracer 236, Thermo Scientific) in assay 
buffer for 60 min at room temperature. During the incubation time the plate (384 white low volume plate, 3674, 
Corning) was covered with foil. The assay was then read on an EnVision™ 2103 multi label microplate reader.
DELFIA autophosphorylation assay. DELFIA autophosphorylation assay on recombinant dephospho-
rylated IRE1α was performed as described previously39.
IRE1α RNase activity analysis. Ribonuclease activity of recombinant IRE1α was analysed using 
FRET derepression assay40. 22.5 nL of the RNA tracer (300 nM, Integrated DNA Technologies, sequence 5′ 
6-FAM-CUG-AGU-CCG-CAG-CAC-UCA-G-3IABkFQ_1-3′ ) was added to the plate (384 black low volume 
plates, 3676, Corning) via the Echo ® 550 acoustic dispenser (Labcyte). This was followed by 5 μ L assay buffer 
(20 mM Hepes pH 7.5, 0.05% Triton X 100 v/v, 1 mM DTT). Then 5 μ L of phosphorylated IRE1 (1 μ g/mL) was 
added to the plate. The plate was centrifuged for 1 min at 1000 rpm. The plate was then read on an EnVision™ 
2103 multi label microplate after 10 min.
Statistical analysis. Data are presented as means ± SEM of at least three independent experiments. 
Data were analysed by one-way ANOVA with Bonferroni post hoc means comparison using Prism software 
(GraphPad). Differences were considered statistically significant for P < 0.05.
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